Literature DB >> 26071461

Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics: A Guide to a Number of Perplexing Entities.

Sa A Wang1, Robert P Hasserjian2.   

Abstract

OBJECTIVES: At the 2013 Society for Hematopathology/European Association for Hematopathology Workshop, 36 cases were submitted to the session that covered acute erythroid leukemia (AEL), acute megakaryoblastic leukemia (AMKL), and reactive mimics.
METHODS: Cases were reviewed by the session chairs and workshop panel to reach a consensus diagnosis.
RESULTS: For acute erythroleukemia, erythroid/myeloid type, discussion acknowledged overlapping features between AEL and myelodysplastic syndromes. Cases submitted as pure erythroid leukemia had distinctive morphology and immunophenotype, complex karyotypes, and aggressive clinical behavior, illustrating certain diagnostic features not currently captured by the current World Health Organization (WHO) definition. In Down syndrome, there were striking similarities between transient abnormal myelopoiesis and AMKL. Most cases of AMKL in adults would be classified as acute myeloid leukemia with myelodysplasia-related changes according to the WHO classification, but this approach deemphasizes their unique clinical, morphologic, and immunophenotypic features.
CONCLUSIONS: The broad spectrum of cases illustrated the difficulties and complex issues involved in establishing a diagnosis of these entities and the need for better disease definitions. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Acute erythroid leukemia; Acute megakaryoblastic leukemia; Down syndrome; Megaloblastic anemia; Pure erythroid leukemia; Transient abnormal myelopoiesis

Mesh:

Year:  2015        PMID: 26071461     DOI: 10.1309/AJCPRKYAT6EZQHC7

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

1.  Molecular evidence of JAK2 p.V617F mutated pure erythroid leukemia arising from polycythemia vera.

Authors:  Alisha D Ware; Jacqueline Birkness; Amy S Duffield; Christopher D Gocke
Journal:  Virchows Arch       Date:  2018-04-02       Impact factor: 4.064

2.  De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity.

Authors:  Erica F Reinig; Patricia T Greipp; April Chiu; Matthew T Howard; Kaaren K Reichard
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

Review 3.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Authors:  Joseph D Khoury; Eric Solary; Oussama Abla; Yassmine Akkari; Rita Alaggio; Jane F Apperley; Rafael Bejar; Emilio Berti; Lambert Busque; John K C Chan; Weina Chen; Xueyan Chen; Wee-Joo Chng; John K Choi; Isabel Colmenero; Sarah E Coupland; Nicholas C P Cross; Daphne De Jong; M Tarek Elghetany; Emiko Takahashi; Jean-Francois Emile; Judith Ferry; Linda Fogelstrand; Michaela Fontenay; Ulrich Germing; Sumeet Gujral; Torsten Haferlach; Claire Harrison; Jennelle C Hodge; Shimin Hu; Joop H Jansen; Rashmi Kanagal-Shamanna; Hagop M Kantarjian; Christian P Kratz; Xiao-Qiu Li; Megan S Lim; Keith Loeb; Sanam Loghavi; Andrea Marcogliese; Soheil Meshinchi; Phillip Michaels; Kikkeri N Naresh; Yasodha Natkunam; Reza Nejati; German Ott; Eric Padron; Keyur P Patel; Nikhil Patkar; Jennifer Picarsic; Uwe Platzbecker; Irene Roberts; Anna Schuh; William Sewell; Reiner Siebert; Prashant Tembhare; Jeffrey Tyner; Srdan Verstovsek; Wei Wang; Brent Wood; Wenbin Xiao; Cecilia Yeung; Andreas Hochhaus
Journal:  Leukemia       Date:  2022-06-22       Impact factor: 12.883

4.  Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.

Authors:  Sa A Wang; Keyur P Patel; Olga Pozdnyakova; Jie Peng; Zhuang Zuo; Paola Dal Cin; David P Steensma; Robert P Hasserjian
Journal:  Mod Pathol       Date:  2016-07-15       Impact factor: 7.842

5.  Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group.

Authors:  Karen M Chisholm; Amy E Heerema-McKenney; John K Choi; Jenny Smith; Rhonda E Ries; Betsy A Hirsch; Susana C Raimondi; Todd A Alonzo; Yi-Cheng Wang; Richard Aplenc; Lillian Sung; Alan S Gamis; Soheil Meshinchi; Samir B Kahwash
Journal:  Blood Adv       Date:  2020-12-08

6.  Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.

Authors:  Alexandre Fagnan; Frederik Otzen Bagger; Maria-Riera Piqué-Borràs; Cathy Ignacimouttou; Alexis Caulier; Cécile K Lopez; Elie Robert; Benjamin Uzan; Véronique Gelsi-Boyer; Zakia Aid; Cécile Thirant; Ute Moll; Samantha Tauchmann; Amina Kurtovic-Kozaric; Jaroslaw Maciejewski; Christine Dierks; Orietta Spinelli; Silvia Salmoiraghi; Thomas Pabst; Kazuya Shimoda; Virginie Deleuze; Hélène Lapillonne; Connor Sweeney; Véronique De Mas; Betty Leite; Zahra Kadri; Sébastien Malinge; Stéphane de Botton; Jean-Baptiste Micol; Benjamin Kile; Catherine L Carmichael; Ilaria Iacobucci; Charles G Mullighan; Martin Carroll; Peter Valent; Olivier A Bernard; Eric Delabesse; Paresh Vyas; Daniel Birnbaum; Eduardo Anguita; Loïc Garçon; Eric Soler; Juerg Schwaller; Thomas Mercher
Journal:  Blood       Date:  2020-08-06       Impact factor: 25.476

7.  Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma.

Authors:  Kalyan Nadiminti; M Hasib Sidiqi; Kapil Meleveedu; Hassan B Alkhateeb; William J Hogan; Mark Litzow; Mrinal Patnaik; Shaji Kumar; Morie Gertz; Dong Chen; Mithun Vinod Shah
Journal:  Blood Cancer J       Date:  2021-03-19       Impact factor: 9.812

8.  Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases.

Authors:  Hong Fang; Sa A Wang; Joseph D Khoury; Siba El Hussein; Do Hwan Kim; Mehrnoosh Tashakori; Zhenya Tang; Shaoying Li; Zhihong Hu; Fatima Zahra Jelloul; Keyur P Patel; Timothy J McDonnell; Tapan Kadia; L Jeffrey Medeiros; Wei Wang
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.